» Articles » PMID: 35720360

Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications

Overview
Journal Front Immunol
Date 2022 Jun 20
PMID 35720360
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma is a primary malignant tumor that tends to threaten children and adolescents, and the 5-year event-free survival rate has not improved significantly in the past three decades, bringing grief and economic burden to patients and society. To date, the genetic background and oncogenesis mechanisms of osteosarcoma remain unclear, impeding further research. The tumor immune microenvironment has become a recent research hot spot, providing novel but valuable insight into tumor heterogeneity and multifaceted mechanisms of tumor progression and metastasis. However, the immune microenvironment in osteosarcoma has been vigorously discussed, and the landscape of immune and non-immune component infiltration has been intensively investigated. Here, we summarize the current knowledge of the classification, features, and functions of the main infiltrating cells, complement system, and exosomes in the osteosarcoma immune microenvironment. In each section, we also highlight the complex crosstalk network among them and the corresponding potential therapeutic strategies and clinical applications to deepen our understanding of osteosarcoma and provide a reference for imminent effective therapies with reduced adverse effects.

Citing Articles

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives.

Hu Y, Yang R, Ni S, Song Z Front Immunol. 2025; 15:1485053.

PMID: 39995821 PMC: 11847827. DOI: 10.3389/fimmu.2024.1485053.


Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics.

Li B, Zhang C, Xu X, Shen Q, Luo S, Hu J Front Immunol. 2025; 16:1539396.

PMID: 39991153 PMC: 11842356. DOI: 10.3389/fimmu.2025.1539396.


Interfering with UBE2L3 expression targets regulation of MLKL to promote necroptosis inhibition of growth in osteosarcoma.

Zhao X, Shan G, Xing D, Gao H, Xiong Z, Hui W World J Surg Oncol. 2025; 23(1):63.

PMID: 39988669 PMC: 11849225. DOI: 10.1186/s12957-025-03715-3.


Using β-Elemene to reduce stemness and drug resistance in osteosarcoma: A focus on the AKT/FOXO1 signaling pathway and immune modulation.

Zhang S, Xing Z, Ke J J Bone Oncol. 2025; 50():100655.

PMID: 39850453 PMC: 11755076. DOI: 10.1016/j.jbo.2024.100655.


Exploration of metastasis-related signatures in osteosarcoma based on tumor microenvironment by integrated bioinformatic analysis.

Liao S, Gao X, Zhou K, Kang Y, Ji L, Zhong X Heliyon. 2025; 11(1):e41358.

PMID: 39844989 PMC: 11750479. DOI: 10.1016/j.heliyon.2024.e41358.


References
1.
Clayton A, Mitchell J, Court J, Mason M, Tabi Z . Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007; 67(15):7458-66. DOI: 10.1158/0008-5472.CAN-06-3456. View

2.
Meyers P, Schwartz C, Krailo M, Healey J, Bernstein M, Betcher D . Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008; 26(4):633-8. DOI: 10.1200/JCO.2008.14.0095. View

3.
Lagerweij T, Perez-Lanzon M, Baglio S . A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells. J Vis Exp. 2018; (135). PMC: 6101124. DOI: 10.3791/56932. View

4.
Zhang C, Zheng J, Lin Z, Lv H, Ye Z, Chen Y . Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging (Albany NY). 2020; 12(4):3486-3501. PMC: 7066877. DOI: 10.18632/aging.102824. View

5.
Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W . Tumor-derived Exosomes Induced M2 Macrophage Polarization and Promoted the Metastasis of Osteosarcoma Cells Through Tim-3. Arch Med Res. 2020; 52(2):200-210. DOI: 10.1016/j.arcmed.2020.10.018. View